• 1. Enantiocontrolled construction of sistodiolynne, an unusual polyketide from the wood-decay fungus Sistrema raduloides
  Chem. Commun., 1997, 767-768
• 2. Emergence of cationic polyamine dendrimersomes: design, stimuli sensitivity and potential biomedical applications
  Partha Laskar,Christine Dufès Nanoscale Adv., 2021,3, 6007-6026
• 3. Examination of ammonia–poly(pyrrole) interactions by piezoelectric and conductivity measurements
  Analyst, 1991,116, 1125-1130
• 4. Excellent electrochemical performance of LiFe0.4Mn0.6PO4 microspheres produced using a double carbon coating process?
  Yong Ping Huang,Tao Tao,Zheng Chen,Wei Han,Ying Wu,Chunjiang Kuang,Shaoxiong Zhou,Ying Chen J. Mater. Chem. A, 2014,2, 18831-18837
• 5. Evolution in surface coverage of CH3NH3PbI3?XClXvia heat assisted solvent vapour treatment and their effects on photovoltaic performance of devices
  Dhirendra K. Chaudhary,Pramendra Kumar,Lokendra Kumar RSC Adv., 2016,6, 94731-94738

Comprehensive Guide to tert-butyl 3,3-difluoro-4-(pyrrolidin-1-yl)piperidine-1-carboxylate (CAS No. 1686139-26-3)

tert-butyl 3,3-difluoro-4-(pyrrolidin-1-yl)piperidine-1-carboxylate (CAS No. 1686139-26-3) is a highly specialized fluorinated piperidine derivative that has garnered significant attention in pharmaceutical and agrochemical research. This compound, characterized by its unique difluorinated structure and tert-butyl carboxylate group, serves as a critical intermediate in the synthesis of bioactive molecules. Its molecular formula is C14H24F2N2O2, and it features a pyrrolidine substitution at the 4-position of the piperidine ring, enhancing its potential for diverse applications.

The growing interest in fluorinated compounds like tert-butyl 3,3-difluoro-4-(pyrrolidin-1-yl)piperidine-1-carboxylate is driven by their ability to improve the metabolic stability and bioavailability of drug candidates. Researchers are particularly intrigued by the role of fluorine atoms in modulating lipophilicity and binding affinity, making this compound a valuable asset in medicinal chemistry. Recent studies highlight its utility in the development of CNS-targeting drugs, where the pyrrolidine moiety contributes to enhanced blood-brain barrier penetration.

In the context of green chemistry, tert-butyl 3,3-difluoro-4-(pyrrolidin-1-yl)piperidine-1-carboxylate aligns with the demand for sustainable synthetic intermediates. Its difluorinated structure reduces the need for harsh reagents, aligning with global trends toward eco-friendly manufacturing. The compound’s stability under mild conditions also makes it suitable for flow chemistry applications, a hot topic in modern process optimization.

From a commercial perspective, CAS No. 1686139-26-3 is gaining traction in custom synthesis and contract research organizations (CROs). Its versatility as a building block for heterocyclic compounds has led to increased procurement by pharmaceutical companies exploring novel kinase inhibitors and GPCR modulators. Market analysts note a rise in patents referencing this compound, particularly in oncology and neurology pipelines.

For researchers handling tert-butyl 3,3-difluoro-4-(pyrrolidin-1-yl)piperidine-1-carboxylate, proper storage at -20°C under inert atmosphere is recommended to preserve its integrity. Analytical methods such as HPLC and NMR are typically employed for purity verification (>98%). As the industry shifts toward AI-driven drug discovery, this compound’s well-defined physicochemical properties make it an ideal candidate for in silico screening libraries.

The synthesis of tert-butyl 3,3-difluoro-4-(pyrrolidin-1-yl)piperidine-1-carboxylate typically involves multi-step routes starting from piperidone derivatives, with electrophilic fluorination as a key step. Recent advancements in catalytic fluorination techniques have improved yields and reduced byproducts, addressing scalability challenges. These innovations resonate with the pharmaceutical industry’s focus on cost-effective API manufacturing.

In summary, CAS No. 1686139-26-3 represents a convergence of cutting-edge fluorine chemistry and practical drug design. Its structural features cater to evolving needs in precision medicine and fragment-based drug discovery, while its commercial availability supports accelerated research timelines. As the scientific community continues to explore privileged scaffolds, this compound is poised to remain a focal point in high-value applications.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)